8-K: Tharimmune Boosts Authorized Shares to 1 Billion

Tharimmune, Inc. amended its Certificate of Incorporation to increase authorized common stock from 250 million to 1 billion shares and establish 10 million preferred shares.

Summary

• Tharimmune, Inc. filed a Certificate of Amendment to its Certificate of Incorporation on October 10, 2025.
• The amendment increased the total number of authorized shares of Common Stock from 250,000,000 to 1,000,000,000.
• The aggregate number of shares the corporation now has authority to issue is 1,010,000,000, consisting of 1,000,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock.
• Both Common Stock and Preferred Stock have a par value of $0.0001.
• The Board of Directors is authorized to determine and alter the rights, preferences, privileges, and restrictions of any unissued series of Preferred Stock.
• Stockholders of the Corporation duly approved this amendment.

Sentiment

Score: 5

Explanation: The increase in authorized shares is a structural corporate governance change. While it provides the company with flexibility for future growth and capital raises, it also introduces the potential for shareholder dilution, making its immediate sentiment neutral without further context on its intended use.

Negatives

• The significant increase in authorized shares introduces the potential for future shareholder dilution if new shares are issued.

Risks

• Future equity offerings utilizing the increased authorized shares could dilute the ownership percentage of existing shareholders.
• An increased supply of available shares on the market could put downward pressure on the stock price.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the structural change to the company's authorized share capital.

Industry Context

Increasing authorized shares is a common corporate action, particularly for growth-oriented companies, to provide flexibility for future capital raises, strategic acquisitions, stock-based compensation plans, or other corporate purposes. This move aligns Tharimmune with practices that allow for greater agility in financing and strategic maneuvers within the biotechnology or pharmaceutical industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution of ownership and earnings per share if new shares are issued, but also enables the company to raise capital for growth.
• Company Management: Gains increased flexibility in financing and strategic options, including the ability to use stock for acquisitions or compensation.

Key Dates

Recommendation

The increase in authorized shares provides Tharimmune with significant flexibility for future strategic initiatives, including potential capital raises. While this enables growth, it also introduces the risk of future shareholder dilution. A 'hold' recommendation is appropriate until the company clarifies its specific plans for these additional shares, allowing investors to assess the potential impact on valuation and ownership.

Keywords

Tharimmune, THAR, authorized shares, common stock, preferred stock, corporate governance, SEC filing, 8-K, stock dilution, capital structure